Afirma基因测序分类器对甲状腺细针穿刺临床实践的影响
单中心回顾性分析2481例甲状腺细针穿刺,比较Afirma基因测序分类器引入前后19个月的意义不明异型性(AUS)比例。因AUS行甲状腺切除术的患者中恶性肿瘤比例从23%升至41%,手术等待时间无显著变化。
要点
- 因AUS行甲状腺切除术者恶性肿瘤比例由23%升至41%。
核心结论
- 基因测序分类器的一个非预期后果是AUS比例增加,且意外地主要见于经验更丰富的细胞病理学家。
- 基因测序分类器与因AUS行甲状腺切除术患者恶性肿瘤绝对增加18%相关,手术等待时间无显著变化。
研究设计与样本
- 共纳入2481例甲状腺细针穿刺,其中基因测序分类器引入前1164例、引入后1317例。
- 细胞病理学家共6名,按经验分为<15年或≥15年两组。
主要发现
- 引入前39例AUS患者行甲状腺切除术,30例(77%)良性、9例(23%)恶性,中位手术等待147天(IQR 89-308.5)。
- 引入后51例AUS患者行甲状腺切除术,30例(59%)良性、21例(41%)恶性,中位手术等待151天(IQR 66-249)。
临床怎么用
- 临床应关注基因测序分类器引入后AUS诊断比例上升及其对手术决策的潜在影响。
- 对AUS患者行甲状腺切除术时需注意恶性肿瘤比例可能升高,但手术等待时间未见明显缩短。
局限性
- 单中心回顾性研究,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing is a diagnostic adjunct that refines cancer risk assessment of cytologically indeterminate thyroid nodules. The aim of this study was to investigate the impact of the Afirma gene sequencing classifier on clinical practice. Our hypothesis was that the gene sequencing classifier has led to an increased rate of atypia of undetermined significance. METHODS: A single-center retrospective analysis of thyroid fine-needle aspiration was performed from October 2021 to January 2025. Rates of atypia of undetermined significance for 19 months before and after the introduction of the gene sequencing classifier were compared. Cytopathologists (n = 6) were divided into those with <15 years or ≥15 years of experience. RESULTS: There were 2,481 thyroid fine-needle aspirations: 1,164 pre-gene sequencing classifier and 1,317 post-gene sequencing classifier. Pre-gene sequencing classifier, 16% of fine-needle aspirations were atypia of undetermined significance compared with 20% post-gene sequencing classifier (P = .003). Following implementation of the gene sequencing classifier, there was an increase in atypia of undetermined significance from 18% to 20% for less experienced cytopathologists (P = .4), compared with 15%-20% for more experienced cytopathologists (P = .004). Pre-gene sequencing classifier, 39 patients with atypia of undetermined significance underwent thyroidectomy; 30 (77%) had benign disease and 9 (23%) had cancer. Median days to surgery was 147 (interquartile range, 89-308.5). Post-gene sequencing classifier, 51 patients with atypia of undetermined significance underwent thyroidectomy; 30 (59%) had benign disease and 21 (41%) had cancer. Median days to surgery was 151 (interquartile range, 66-249). CONCLUSION: An unintended consequence of the gene sequencing classifier was an increase in atypia of undetermined significance, a phenomenon unexpectedly observed among more experienced cytopathologists. The gene sequencing classifier was associated with an 18% absolute increase in malignancy for patients undergoing thyroidectomy for atypia of undetermined significance without significant change in time to surgery.
引用
- Leng J, Amer Y, Turza A, et al. Expected, unexpected, and unintended consequences of the Afirma gene sequencing classifier. Surgery. 2026. PMID: 42791096. doi:10.1016/j.surg.2026.110619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。